Fortis Healthcare Board Approves Audited FY26 Results, Recommends ₹1 Dividend
Fortis Healthcare's Board approved audited FY26 results. The company reported consolidated revenue of ₹912,784 lacs for the year ended March 31, 2026. A final dividend of ₹1 per equity share was recommended, subject to member approval. M/s Jitender, Navneet & Co. appointed as Cost Auditor for FY26-27.
The approval of audited financial results and the recommendation of a dividend are significant events for shareholders and stakeholders, impacting investment decisions and company valuation.
The company reported its audited financial results with an unmodified opinion from auditors and recommended a dividend, indicating positive financial health and shareholder returns.
Fortis Healthcare Limited announced the outcome of its Board Meeting held on Friday, May 22, 2026. The Board approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. The Statutory Auditors, M/s. B S R & Co. LLP, issued an audit report with an unmodified opinion on these results.
Additionally, the Board recommended a final dividend of ₹1 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid/dispatched within 30 days of the AGM's conclusion, if approved.
The Board also approved the appointment of M/s Jitender, Navneet & Co., Cost Accountants, as the Cost Auditor for the Financial Year 2026-27. Furthermore, the policy of Corporate Social Responsibility was approved by the Board.
The financial results for the quarter and year ended March 31, 2026, show consolidated revenue from operations of ₹236,467 lacs for the quarter and ₹912,784 lacs for the year. Net profit attributable to owners of the Company for the year stood at ₹104,178 lacs.
The Board meeting commenced at 09:35 Hours IST and concluded at 19:35 Hours IST.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.